This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

This study has been completed.
Information provided by (Responsible Party):
Abbott ( Abbott Products ) Identifier:
First received: November 23, 2012
Last updated: June 13, 2014
Last verified: June 2014
The purpose of this study is to evaluate the safety and tolerability of Creon micro in children younger than four years with pancreatic exocrine insufficiency.

Condition Intervention Phase
Pancreatic Exocrine Insufficiency Drug: Pancreatin Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Resource links provided by NLM:

Further study details as provided by Abbott ( Abbott Products ):

Primary Outcome Measures:
  • Body Weight [ Time Frame: 3 months ]
    change from baseline at day 84

  • Height [ Time Frame: 3 months ]
    change from baseline at day 84

  • Stool Frequency [ Time Frame: 3 months ]
    Average daily stool frequency during treatment period: Number of bowel movements per day

  • Stool Consistency [ Time Frame: 3 months ]
    Assessment of stool consistency by the caregiver on a daily basis: hard, formed/normal, soft, watery

  • Subject's Acceptance of Treatment [ Time Frame: 3 months ]
    Acceptance to Creon Micro. The caregiver should give his/her opinion based on the following scale: very good, good, moderate, and unsatisfactory.

Secondary Outcome Measures:
  • Number of Subjects With Adverse Events [ Time Frame: 4 months ]
  • Pulse [ Time Frame: 3 months ]
    Change from Baseline at Day 84

  • Number of Participants With Findings During Physical Examination [ Time Frame: 3 months ]
    A physical examination was conducted by the physician. All abnormal findings were recorded as medical histories if present prior to start of study drug or as AEs otherwise. There was no separate documentation of physical examination findings in this study.

  • Number of Participants With Clinical Relevant Safety Laboratory Values [ Time Frame: 3 months ]
    (hematology: hemoglobin, hematocrit, RBC count, WBC count, platelet count; biochemistry: glucose (fasting), creatinine, alkaline phosphatase, total bilirubin, ALAT (alanine amino transferase), ASAT (aspartate amino transferase), gamma-glutamyl transferase, uric acid, calcium, phosphate, potassium, serum pancreatic lipase; urinalysis (dipstick): glucose, blood, albumin, pH)

Enrollment: 40
Study Start Date: June 2012
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Creon micro, minimicrospheres Drug: Pancreatin
Doses of Pancreatin <2500 lipase u/kg/feed or <4000 lipase U/g fat/intake or <10000 lipase U/kg/day given orally are used
Other Name: Creon micro

Detailed Description:
A prospective open-label, multi-center study evaluating safety and tolerability of Creon Micro in pediatric subjects from at least one month to less than four years of age with Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis (CF). Referring to the European Medicines Agency (EMEA) pediatric age criteria for the purpose of the study, subjects are categorized as infants and toddlers (< 2 years) and children, (2 years to < 4 years). In total, 40 subjects will be enrolled (20 subjects in each age subgroup). Subjects receive their prescribed pancreatic enzyme supplementation at the individual dose until start of treatment with Creon Micro, if the subjects were on pancreatic enzyme supplementation before start of the study. Subjects will be treated with Creon Micro during the study. The treatment duration is 3 months.

Ages Eligible for Study:   up to 4 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children younger than four years with confirmed cystic fibrosis diagnosis and a body weight of at least 2 kilograms

Exclusion Criteria:

  • Ileus or acute abdomen
  • history of fibrosing colonopathy
  • history of distal ileal obstruction without surgery
  • solid organ transplant or surgery affecting the large bowel, other than appendectomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01747330

Russian Federation
Site Reference ID/Investigator# 80716
Barnaul, Russian Federation, 656019
Site Reference ID/Investigator# 80693
Moscow, Russian Federation, 117997
Site Reference ID/Investigator# 80698
Novosibirsk, Russian Federation, 630091
Site Reference ID/Investigator# 80713
Novosibirsk, Russian Federation
Site Reference ID/Investigator# 80715
Orenburg, Russian Federation, 460000
Site Reference ID/Investigator# 80694
St. Petersburg, Russian Federation, 194156
Site Reference ID/Investigator# 80714
Tomsk, Russian Federation, 634050
Site Reference ID/Investigator# 80697
Voronezh, Russian Federation, 394036
Site Reference ID/Investigator# 80696
Yaroslavl, Russian Federation, 150003
Sponsors and Collaborators
Abbott Products
Study Director: Suntje Sander-Struckmeier, PhD Abbott
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Abbott Products Identifier: NCT01747330     History of Changes
Other Study ID Numbers: M13-277
Study First Received: November 23, 2012
Results First Received: December 23, 2013
Last Updated: June 13, 2014

Keywords provided by Abbott ( Abbott Products ):
cystic fibrosis

Additional relevant MeSH terms:
Cystic Fibrosis
Exocrine Pancreatic Insufficiency
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Gastrointestinal Agents processed this record on September 18, 2017